EPO and anemia (phenotype): In an open-label study of children aged 1–18 years with an estimated glomerular filtration rate (eGFR) of <30 ml/min × 1.73 m2, DA was found to be non-inferior to recombinant human erythropoietin (rHuEpo) for treating anemia [12], but the follow-up in this and other studies that evaluated the use of DA in children aged <11 years [13–16] was limited to 28 weeks.